Brevan Howard Capital Management 13F: New $19M Stake in ABBV
Brevan Howard Capital Management has initiated a new stake in AbbVie Inc., acquiring 73,583 shares valued at about $18.6 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brevan Howard Capital Management opened a new position of 73,583 shares in AbbVie Inc. ($ABBV), according to a 13F filing with the SEC dated May 15, 2026. It reported 73,583 shares worth $18.59 million at the end of the quarter.
Since the filing, $ABBV is up 2.5% after 1 week, up 5.3% after 1 month and up 37.5% to date (from the $207.63 close on May 15, 2026).
Find the original: Brevan Howard Capital Management 13F filings on SEC EDGAR
ABBV
AbbVie Inc.
Key Points
- Brevan Howard Capital Management has taken a new position in AbbVie Inc. by acquiring 73,583 shares worth approximately $18.6 million as of May 15, 2026.
- AbbVie shares are trading at $252.59, which is near the middle of its 52-week range of $190.75 to $267.47, indicating stable performance recently.
- Other institutional investors, like BlackRock and Vanguard, have adjusted their holdings in AbbVie, showcasing varied interest in the stock.
Get $ABBV trade alerts by text
We text you when insiders, Congress or big funds trade $ABBV. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Brevan Howard Capital Management has taken a new position in AbbVie Inc. (NYSE: ABBV), acquiring 73,583 shares valued at approximately $18.6 million. This filing reflects holdings as of May 15, 2026, according to the latest Form 13F filed with the SEC. The shares were purchased at an average cost basis of $221.41.
What Changed in Brevan Howard's AbbVie Position
Brevan Howard's stake in AbbVie is a new buy, starting with 73,583 shares. This marks a significant entry into the company for the fund, which didn't hold any shares previously.
Other Institutional Activity in AbbVie
BlackRock Inc. reduced its holdings by 1,205,552 shares, ending with 149,488,412 shares valued at about $42.7 billion. Vanguard Capital Management LLC added 516,956 shares, bringing its total to 115,396,098 shares worth approximately $32.9 billion. State Street Corporation grew its position by 1,380,673 shares, reaching a total of 82,596,748 shares valued at about $23.6 billion. Vanguard Portfolio Management LLC trimmed its stake by 1,044,934 shares, ending with 48,477,996 shares valued at around $13.8 billion. JPMorgan Chase & Co also cut its holdings by 8,880,294 shares, leaving it with 47,862,796 shares worth approximately $13.7 billion.
AbbVie Inc. Stock Down 10.9%
AbbVie is currently trading at $252.59, which is well-positioned in its 52-week range of $190.75 to $267.47. The stock price is close to its 50-day moving average of $255.68, suggesting it has maintained relative stability in recent weeks.
Recent Earnings
In its most recent earnings report, AbbVie reported revenue of $64.4 billion, representing a growth of 10.2%. The company had an EPS of $3.54 and a net margin of 9.8%. AbbVie is set to report its next earnings on October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie currently pays an annual dividend rate of $6.92, translating to a yield of 2.62%. The dividend payout ratio is notably high at 190.4%, indicating a significant portion of earnings is allocated to dividends.
Insider Buying and Selling at AbbVie Inc.
Recent insider activity includes sales from several executives. Nicholas Donoghoe, an officer at AbbVie, sold 32,710 shares at $250.00 each for a total value of $8,177,500 on August 14, 2026. David Ryan Purdue, another officer, sold 5,230 shares at $233.56 each, totaling around $1,221,519 on March 4, 2026. Additionally, Perry C. Siatis, General Counsel, sold 18,668 shares without a specified price for a total value of approximately $4,375,549 on March 2, 2026.
Analysts Set New Price Targets
On October 13, 2026, RBC Capital reiterated its rating of "Outperform" with a price target of $280.00. UBS maintained a "Neutral" rating with a target set at $275.00, while Guggenheim reaffirmed its "Buy" rating with a target of $288.00. JP Morgan and Cantor Fitzgerald both maintained their "Overweight" ratings with targets of $300.00 and $290.00 respectively.
About AbbVie
AbbVie Inc. is a biopharmaceutical company focused on developing and selling medicines and therapies globally. It specializes in treatments for autoimmune diseases, cancer, and inflammatory conditions, among others. Brevan Howard's new stake may signal confidence in AbbVie's growing portfolio and market position.
Bottom Line
Investors should watch for AbbVie's upcoming earnings report on October 29, 2026, to see how the company continues to perform. With Brevan Howard now holding a significant position, future filings may reveal how this stake evolves over time. Remember, this filing reflects holdings as of May 15, 2026, and may not represent Brevan Howard's current position.
Related Filing Alerts
Source: Brevan Howard Capital Management's 13F filing on $ABBV (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Brevan Howard Capital Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts